DUBLIN, Aug. 6, 2019/PRNewswire/ --
SECOND QUARTER 2019 FINANCIAL RESULTS
(unaudited; $ in millions, except per share |
Q2 '19 |
Q2 '18 |
Q2 '19 v Q2 '18 |
Six |
Six |
2019 v |
||||||||||||||||||
Total Net Revenues |
$ |
4,090.1 |
$ |
4,124.2 |
(0.8) |
% |
$ |
7,687.2 |
$ |
7,796.3 |
(1.4) |
% |
||||||||||||
Operating (Loss) |
$ |
(1,262.9) |
$ |
(467.0) |
(170.4) |
% |
$ |
(3,572.1) |
$ |
(1,121.0) |
(218.7) |
% |
||||||||||||
Diluted EPS |
$ |
(5.37) |
$ |
(1.39) |
(286.3) |
% |
$ |
(12.63) |
$ |
(2.39) |
(428.5) |
% |
||||||||||||
SG&A Expense |
$ |
1,197.5 |
$ |
1,187.5 |
0.8 |
% |
$ |
2,309.8 |
$ |
2,283.4 |
1.2 |
% |
||||||||||||
R&D Expense |
$ |
450.0 |
$ |
689.2 |
(34.7) |
% |
$ |
885.0 |
$ |
1,163.9 |
(24.0) |
% |
||||||||||||
Tax Rate |
(20.8) |
% |
1.1 |
% |
(21.9) |
% |
(5.9) |
% |
47.7 |
% |
(53.6) |
% |
||||||||||||
Non-GAAP Net Revenues |
$ |
4,090.1 |
$ |
4,099.2 |
(0.2) |
% |
$ |
7,687.2 |
$ |
7,771.3 |
(1.1) |
% |
||||||||||||
Non-GAAP Operating Income |
$ |
1,850.3 |
$ |
1,973.8 |
(6.3) |
% |
$ |
3,475.9 |
$ |
3,732.9 |
(6.9) |
% |
||||||||||||
Non-GAAP Performance Net Income Per Share |
$ |
4.38 |
$ |
4.42 |
(0.9) |
% |
$ |
8.17 |
$ |
8.16 |
0.1 |
% |
||||||||||||
Non-GAAP Adjusted EBITDA |
$ |
1,952.4 |
$ |
2,086.2 |
(6.4) |
% |
$ |
3,689.4 |
$ |
3,955.9 |
(6.7) |
% |
||||||||||||
Non-GAAP SG&A Expense |
$ |
1,162.8 |
$ |
1,134.4 |
2.5 |
% |
$ |
2,259.0 |
$ |
2,183.1 |
3.5 |
% |
||||||||||||
Non-GAAP R&D Expense |
$ |
447.0 |
$ |
388.9 |
14.9 |
% |
$ |
844.9 |
$ |
744.7 |
13.5 |
% |
||||||||||||
Non-GAAP Tax Rate |
12.8 |
% |
14.3 |
% |
(1.5) |
% |
12.8 |
% |
14.2 |
% |
(1.4) |
% |
||||||||||||
Executive Commentary
"In the second quarter of 2019,
Second Quarter 2019 Results
GAAP operating loss in the second quarter of 2019 was
Operating Expenses
Total GAAP Selling, General and Administrative (SG&A) Expense was
Amortization, Tax and Capitalization
Amortization expense for the second quarter of 2019 was
Asset Sales & Impairments, Net and In-Process R&D Impairments
SECOND QUARTER 2019 BUSINESS SEGMENT RESULTS
U.S. Specialized Therapeutics
U.S. Specialized Therapeutics net revenues were
Medical Aesthetics
Neurosciences & Urology
Eye Care
U.S. General Medicine
U.S. General Medicine net revenues in the second quarter of 2019 were
Central Nervous System
Gastrointestinal,
International
International net revenues in the second quarter of 2019 were
Facial Aesthetics
Eye Care
Botox® Therapeutic
PIPELINE UPDATE
Allergan R&D continues to advance its pipeline. During the second quarter of 2019, the Company's key late-stage clinical developments included:
In addition to second quarter 2019 pipeline developments and the expected launches of Bimatoprost SR, CoolTone™ and abicipar listed above,
OTHER DEVELOPMENTS
On
FULL YEAR 2019 GUIDANCE
Previous Guidance |
Current Guidance |
||||
Twelve Months Ending December 31, 2019 |
Twelve Months Ending December 31, 2019 |
||||
GAAP |
NON-GAAP |
GAAP |
NON-GAAP |
||
Total Net Revenues |
~$15.125 - $15.425 |
~$15.100 - $15.400 |
~$15.425 - $15.625 |
~$15.400 - $15.600 |
|
Gross Margin (as a % of revenues) |
~85.0% - 85.5% |
~85.0% - 85.5% |
~85.0% - 85.5% |
~85.0% - 85.5% |
|
SG&A Expense |
~$4.1 - $4.3 billion |
~$4.1 - $4.3 billion |
~$4.5 - $4.6 billion |
~$4.4 - $4.5 billion |
|
R&D Expense |
~$1.8 - $1.9 billion |
~$1.6 - $1.7 billion |
~$1.8 - $1.9 billion |
~$1.6 - $1.7 billion |
|
Net Interest Expense/Other Income |
~ $775.0 million |
~ $800.0 million |
~ $775.0 million |
~ $800.0 million |
|
Tax Rate |
~ 1.0% |
13.0% - 13.5% |
~ (5.0)% |
~13.0% |
|
Net Income / (Loss) Per Share1 |
>($5.70) |
> $16.55 |
> ($12.03) |
> $16.55 |
|
Average 2019 Share Count2 |
~ 329.0 million |
~ 332.0 million |
~ 329.0 million |
~ 332.0 million |
|
Cash Flow from Operations |
$5.0 - $5.5 billion |
n.a. |
$5.0 - $5.5 billion |
n.a. |
|
(1) GAAP represents EPS for ordinary shareholders. GAAP income per share includes the impact of amortization of approximately $5.7 billion. Non-GAAP represents performance net income per share. |
|||||
(2) GAAP EPS shares do not include dilution of shares when earnings are a net loss. As such, the dilution impact of outstanding equity awards is not included in the forecasted shares. |
ADDITIONAL SECOND QUARTER DETAILS
Due to the proposed acquisition of
Allergan Contacts: |
|
Investors: |
|
Manisha Narasimhan, PhD |
(862) 261-7162 |
Christine Chiou |
(862) 261-7396 |
Media: |
|
Lisa Brown |
(862) 261-7320 |
About
With colleagues and commercial operations located in approximately 100 countries,
For more information, visit
Forward-Looking Statement
Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect
Statements Required by the Irish Takeover Rules
To the extent that the earnings guidance contained, referred to or summarized in this press release constitute a profit forecast for the purposes of Rule 28 of the Irish Takeover Panel Act, Takeover Rules, 2013, such guidance will (unless the
The directors of
Any holder of 1% or more of any class of relevant securities of
The following presents Allergan plc's statement of operations for the three and six months ended June 30, 2019 and 2018: |
||||||||||||||||||||
Table 1 |
||||||||||||||||||||
ALLERGAN PLC |
||||||||||||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS |
||||||||||||||||||||
(Unaudited; in millions, except per share amounts) |
||||||||||||||||||||
Three Months Ended |
Six Months Ended |
|||||||||||||||||||
June 30 |
June 30 |
|||||||||||||||||||
2019 |
2018 |
2019 |
2018 |
|||||||||||||||||
Net revenues |
$ |
4,090.1 |
$ |
4,124.2 |
$ |
7,687.2 |
$ |
7,796.3 |
||||||||||||
Operating expenses: |
||||||||||||||||||||
Cost of sales (excludes amortization and impairment of acquired |
652.3 |
481.8 |
1,150.1 |
1,004.6 |
||||||||||||||||
Research and development |
450.0 |
689.2 |
885.0 |
1,163.9 |
||||||||||||||||
Selling, general and administrative |
1,197.5 |
1,187.5 |
2,309.8 |
2,283.4 |
||||||||||||||||
Amortization |
1,402.0 |
1,697.1 |
2,801.4 |
3,394.7 |
||||||||||||||||
In-process research and development impairments |
436.0 |
276.0 |
436.0 |
798.0 |
||||||||||||||||
Goodwill and other asset impairments / sales, net |
1,215.2 |
259.6 |
3,677.0 |
272.7 |
||||||||||||||||
Total operating expenses |
5,353.0 |
4,591.2 |
11,259.3 |
8,917.3 |
||||||||||||||||
Operating (loss) |
(1,262.9) |
(467.0) |
(3,572.1) |
(1,121.0) |
||||||||||||||||
Non-operating income (expense): |
||||||||||||||||||||
Interest income |
9.7 |
6.3 |
31.0 |
23.6 |
||||||||||||||||
Interest (expense) |
(195.4) |
(230.0) |
(397.2) |
(480.6) |
||||||||||||||||
Other income (expense), net |
(4.7) |
215.4 |
9.1 |
136.6 |
||||||||||||||||
Total other income (expense), net |
(190.4) |
(8.3) |
(357.1) |
(320.4) |
||||||||||||||||
(Loss) before income taxes and noncontrolling interest |
(1,453.3) |
(475.3) |
(3,929.2) |
(1,441.4) |
||||||||||||||||
(Benefit) for income taxes |
301.6 |
(5.2) |
233.0 |
(687.4) |
||||||||||||||||
Net (loss) |
(1,754.9) |
(470.1) |
(4,162.2) |
(754.0) |
||||||||||||||||
(Income) attributable to noncontrolling interest |
(4.1) |
(2.4) |
(4.8) |
(4.6) |
||||||||||||||||
Net (loss) attributable to shareholders |
(1,759.0) |
(472.5) |
(4,167.0) |
(758.6) |
||||||||||||||||
Dividends on preferred shares |
- |
- |
- |
46.4 |
||||||||||||||||
Net (loss) attributable to ordinary shareholders |
$ |
(1,759.0) |
$ |
(472.5) |
$ |
(4,167.0) |
$ |
(805.0) |
||||||||||||
(Loss) per share attributable to ordinary shareholders: |
||||||||||||||||||||
Net (loss) per share - basic |
$ |
(5.37) |
$ |
(1.39) |
$ |
(12.63) |
$ |
(2.39) |
||||||||||||
Net (loss) per share - diluted |
(5.37) |
(1.39) |
(12.63) |
(2.39) |
||||||||||||||||
Weighted average shares outstanding: |
||||||||||||||||||||
Basic |
327.8 |
339.1 |
329.9 |
336.9 |
||||||||||||||||
Diluted |
327.8 |
339.1 |
329.9 |
336.9 |
||||||||||||||||
The following table details Allergan plc's product revenue for significant promoted products globally, within the U.S., and international for the three and six months ended June 30, 2019 and 2018. |
||||||||||||||||||||||||||||||||||||||||||||||||
Table 2 |
||||||||||||||||||||||||||||||||||||||||||||||||
ALLERGAN PLC |
||||||||||||||||||||||||||||||||||||||||||||||||
NET REVENUES TOP GLOBAL PRODUCTS |
||||||||||||||||||||||||||||||||||||||||||||||||
(Unaudited; in millions) |
||||||||||||||||||||||||||||||||||||||||||||||||
Three Months Ended June 30, 2019 |
Three Months Ended June 30, 2018 |
Movement |
||||||||||||||||||||||||||||||||||||||||||||||
US |
US |
International |
Corporate |
Total |
US |
US |
International |
Corporate |
Total |
Total |
Total |
|||||||||||||||||||||||||||||||||||||
Botox® |
$ |
699.4 |
$ |
- |
$ |
274.6 |
$ |
- |
$ |
974.0 |
$ |
658.5 |
$ |
- |
$ |
276.0 |
$ |
- |
$ |
934.5 |
$ |
39.5 |
4.2 |
% |
||||||||||||||||||||||||
Restasis® |
310.9 |
- |
11.9 |
- |
322.8 |
318.2 |
- |
16.0 |
- |
334.2 |
(11.4) |
(3.4) |
% |
|||||||||||||||||||||||||||||||||||
Juvederm® Collection |
156.6 |
- |
172.7 |
- |
329.3 |
139.8 |
- |
156.1 |
- |
295.9 |
33.4 |
11.3 |
% |
|||||||||||||||||||||||||||||||||||
Lumigan®/Ganfort® |
62.1 |
- |
90.4 |
- |
152.5 |
73.0 |
- |
100.5 |
- |
173.5 |
(21.0) |
(12.1) |
% |
|||||||||||||||||||||||||||||||||||
Linzess®/Constella® |
- |
196.0 |
4.8 |
- |
200.8 |
- |
191.8 |
6.4 |
- |
198.2 |
2.6 |
1.3 |
% |
|||||||||||||||||||||||||||||||||||
Bystolic® /Byvalson® |
- |
150.5 |
0.5 |
- |
151.0 |
- |
148.1 |
0.6 |
- |
148.7 |
2.3 |
1.5 |
% |
|||||||||||||||||||||||||||||||||||
Alphagan®/Combigan® |
91.6 |
- |
40.9 |
- |
132.5 |
98.1 |
- |
44.6 |
- |
142.7 |
(10.2) |
(7.1) |
% |
|||||||||||||||||||||||||||||||||||
Lo Loestrin® |
- |
145.5 |
- |
- |
145.5 |
- |
127.8 |
- |
- |
127.8 |
17.7 |
13.8 |
% |
|||||||||||||||||||||||||||||||||||
Breast Implants |
67.6 |
- |
(31.4) |
- |
36.2 |
75.9 |
- |
39.9 |
- |
115.8 |
(79.6) |
(68.7) |
% |
|||||||||||||||||||||||||||||||||||
Viibryd®/Fetzima® |
- |
107.8 |
2.7 |
- |
110.5 |
- |
86.7 |
1.6 |
- |
88.3 |
22.2 |
25.1 |
% |
|||||||||||||||||||||||||||||||||||
Eye Drops |
57.8 |
- |
57.3 |
- |
115.1 |
53.8 |
- |
72.4 |
- |
126.2 |
(11.1) |
(8.8) |
% |
|||||||||||||||||||||||||||||||||||
Asacol®/Delzicol® |
- |
31.6 |
9.7 |
- |
41.3 |
- |
32.6 |
12.4 |
- |
45.0 |
(3.7) |
(8.2) |
% |
|||||||||||||||||||||||||||||||||||
Coolsculpting® Consumables |
60.7 |
- |
20.3 |
- |
81.0 |
71.9 |
- |
18.5 |
- |
90.4 |
(9.4) |
(10.4) |
% |
|||||||||||||||||||||||||||||||||||
Coolsculpting® Systems & Add On |
18.2 |
- |
11.6 |
- |
29.8 |
36.4 |
- |
12.4 |
- |
48.8 |
(19.0) |
(38.9) |
% |
|||||||||||||||||||||||||||||||||||
Ozurdex ® |
29.9 |
- |
81.0 |
- |
110.9 |
27.6 |
- |
67.9 |
- |
95.5 |
15.4 |
16.1 |
% |
|||||||||||||||||||||||||||||||||||
Carafate ® /Sulcrate ® |
- |
56.2 |
0.7 |
- |
56.9 |
- |
54.3 |
0.7 |
- |
55.0 |
1.9 |
3.5 |
% |
|||||||||||||||||||||||||||||||||||
Aczone® |
1.8 |
- |
- |
- |
1.8 |
21.1 |
- |
0.1 |
- |
21.2 |
(19.4) |
(91.5) |
% |
|||||||||||||||||||||||||||||||||||
Zenpep® |
- |
70.0 |
- |
- |
70.0 |
- |
55.5 |
- |
- |
55.5 |
14.5 |
26.1 |
% |
|||||||||||||||||||||||||||||||||||
Canasa®/Salofalk® |
- |
8.0 |
4.1 |
- |
12.1 |
- |
45.0 |
4.5 |
- |
49.5 |
(37.4) |
(75.6) |
% |
|||||||||||||||||||||||||||||||||||
Vraylar® |
- |
196.1 |
- |
- |
196.1 |
- |
114.2 |
- |
- |
114.2 |
81.9 |
71.7 |
% |
|||||||||||||||||||||||||||||||||||
Saphris® |
- |
32.6 |
- |
- |
32.6 |
- |
33.8 |
- |
- |
33.8 |
(1.2) |
(3.6) |
% |
|||||||||||||||||||||||||||||||||||
Viberzi® |
- |
50.8 |
0.3 |
- |
51.1 |
- |
44.9 |
0.3 |
- |
45.2 |
5.9 |
13.1 |
% |
|||||||||||||||||||||||||||||||||||
Teflaro® |
- |
37.0 |
- |
- |
37.0 |
- |
32.4 |
0.6 |
- |
33.0 |
4.0 |
12.1 |
% |
|||||||||||||||||||||||||||||||||||
Namzaric® |
- |
22.6 |
- |
- |
22.6 |
- |
31.8 |
- |
- |
31.8 |
(9.2) |
(28.9) |
% |
|||||||||||||||||||||||||||||||||||
Rapaflo® |
4.5 |
- |
1.4 |
- |
5.9 |
19.7 |
- |
1.6 |
- |
21.3 |
(15.4) |
(72.3) |
% |
|||||||||||||||||||||||||||||||||||
Skin Care |
42.6 |
- |
3.7 |
- |
46.3 |
34.3 |
- |
4.1 |
- |
38.4 |
7.9 |
20.6 |
% |
|||||||||||||||||||||||||||||||||||
Kybella® /Belkyra® |
8.5 |
- |
0.6 |
- |
9.1 |
11.2 |
- |
2.3 |
- |
13.5 |
(4.4) |
(32.6) |
% |
|||||||||||||||||||||||||||||||||||
Alloderm® |
101.2 |
- |
2.2 |
- |
103.4 |
107.1 |
- |
2.3 |
- |
109.4 |
(6.0) |
(5.5) |
% |
|||||||||||||||||||||||||||||||||||
Dalvance® |
- |
20.3 |
2.2 |
- |
22.5 |
- |
17.7 |
1.3 |
- |
19.0 |
3.5 |
18.4 |
% |
|||||||||||||||||||||||||||||||||||
Avycaz® |
- |
26.7 |
- |
- |
26.7 |
- |
23.5 |
- |
- |
23.5 |
3.2 |
13.6 |
% |
|||||||||||||||||||||||||||||||||||
Liletta® |
- |
21.9 |
- |
- |
21.9 |
- |
15.5 |
- |
- |
15.5 |
6.4 |
41.3 |
% |
|||||||||||||||||||||||||||||||||||
Namenda® |
- |
6.1 |
- |
- |
6.1 |
- |
3.4 |
- |
- |
3.4 |
2.7 |
79.4 |
% |
|||||||||||||||||||||||||||||||||||
Armour Thyroid |
- |
56.7 |
- |
- |
56.7 |
- |
49.2 |
- |
- |
49.2 |
7.5 |
15.2 |
% |
|||||||||||||||||||||||||||||||||||
Savella® |
- |
22.3 |
- |
- |
22.3 |
- |
19.1 |
- |
- |
19.1 |
3.2 |
16.8 |
% |
|||||||||||||||||||||||||||||||||||
Other Products Revenues |
71.7 |
197.0 |
85.5 |
1.6 |
355.8 |
80.1 |
192.7 |
105.8 |
28.6 |
407.2 |
(51.4) |
(12.6) |
% |
|||||||||||||||||||||||||||||||||||
Total Net Revenues |
$ |
1,785.1 |
$ |
1,455.7 |
$ |
847.7 |
$ |
1.6 |
4,090.1 |
$ |
1,826.7 |
$ |
1,320.0 |
$ |
948.9 |
$ |
28.6 |
4,124.2 |
$ |
(34.1) |
(0.8) |
% |
||||||||||||||||||||||||||
1Botox® is comprised of the following: |
||||||||||||||||||||||||||||||||||||||||||||||||
Botox® Therapeutics |
447.0 |
- |
98.8 |
- |
545.8 |
422.0 |
- |
104.6 |
- |
526.6 |
19.2 |
3.6 |
% |
|||||||||||||||||||||||||||||||||||
Botox® Cosmetics |
252.4 |
- |
175.8 |
- |
428.2 |
236.5 |
- |
171.4 |
- |
407.9 |
20.3 |
5.0 |
% |
|||||||||||||||||||||||||||||||||||
Six Months Ended June 30, 2019 |
Six Months Ended June 30, 2018 |
Movement |
||||||||||||||||||||||||||||||||||||||||||||||
US |
US |
International |
Corporate |
Total |
US |
US |
International |
Corporate |
Total |
Total |
Total |
|||||||||||||||||||||||||||||||||||||
Botox® |
$ |
1,326.5 |
$ |
- |
$ |
515.9 |
$ |
- |
$ |
1,842.4 |
$ |
1,231.0 |
$ |
- |
$ |
520.8 |
$ |
- |
$ |
1,751.8 |
$ |
90.6 |
5.2 |
% |
||||||||||||||||||||||||
Restasis® |
542.6 |
- |
22.3 |
- |
564.9 |
574.0 |
- |
34.3 |
- |
608.3 |
(43.4) |
(7.1) |
% |
|||||||||||||||||||||||||||||||||||
Juvederm® Collection |
286.3 |
- |
330.5 |
- |
616.8 |
262.6 |
- |
302.2 |
- |
564.8 |
52.0 |
9.2 |
% |
|||||||||||||||||||||||||||||||||||
Lumigan®/Ganfort® |
119.8 |
- |
175.5 |
- |
295.3 |
139.8 |
- |
200.9 |
- |
340.7 |
(45.4) |
(13.3) |
% |
|||||||||||||||||||||||||||||||||||
Linzess®/Constella® |
- |
357.3 |
10.3 |
- |
367.6 |
- |
351.1 |
12.0 |
- |
363.1 |
4.5 |
1.2 |
% |
|||||||||||||||||||||||||||||||||||
Bystolic® /Byvalson® |
- |
278.8 |
0.9 |
- |
279.7 |
- |
280.9 |
1.1 |
- |
282.0 |
(2.3) |
(0.8) |
% |
|||||||||||||||||||||||||||||||||||
Alphagan®/Combigan® |
174.6 |
- |
78.5 |
- |
253.1 |
182.3 |
- |
88.8 |
- |
271.1 |
(18.0) |
(6.6) |
% |
|||||||||||||||||||||||||||||||||||
Lo Loestrin® |
- |
271.3 |
- |
- |
271.3 |
- |
242.4 |
- |
- |
242.4 |
28.9 |
11.9 |
% |
|||||||||||||||||||||||||||||||||||
Breast Implants |
128.8 |
- |
(20.2) |
- |
108.6 |
136.6 |
- |
84.0 |
- |
220.6 |
(112.0) |
(50.8) |
% |
|||||||||||||||||||||||||||||||||||
Viibryd®/Fetzima® |
- |
192.8 |
4.8 |
- |
197.6 |
- |
158.4 |
3.1 |
- |
161.5 |
36.1 |
22.4 |
% |
|||||||||||||||||||||||||||||||||||
Eye Drops |
107.2 |
- |
112.7 |
- |
219.9 |
100.0 |
- |
141.2 |
- |
241.2 |
(21.3) |
(8.8) |
% |
|||||||||||||||||||||||||||||||||||
Asacol®/Delzicol® |
- |
56.3 |
20.0 |
- |
76.3 |
- |
70.8 |
24.1 |
- |
94.9 |
(18.6) |
(19.6) |
% |
|||||||||||||||||||||||||||||||||||
Coolsculpting® Consumables |
108.5 |
- |
38.1 |
- |
146.6 |
125.3 |
- |
26.6 |
- |
151.9 |
(5.3) |
(3.5) |
% |
|||||||||||||||||||||||||||||||||||
Coolsculpting® Systems & Add On |
33.3 |
- |
22.2 |
- |
55.5 |
70.1 |
- |
13.5 |
- |
83.6 |
(28.1) |
(33.6) |
% |
|||||||||||||||||||||||||||||||||||
Alloderm® |
196.2 |
- |
3.8 |
- |
200.0 |
206.6 |
- |
4.5 |
- |
211.1 |
(11.1) |
(5.3) |
% |
|||||||||||||||||||||||||||||||||||
Ozurdex ® |
60.2 |
- |
144.1 |
- |
204.3 |
53.1 |
- |
132.3 |
- |
185.4 |
18.9 |
10.2 |
% |
|||||||||||||||||||||||||||||||||||
Carafate ® /Sulcrate ® |
- |
110.5 |
1.3 |
- |
111.8 |
- |
110.3 |
1.4 |
- |
111.7 |
0.1 |
0.1 |
% |
|||||||||||||||||||||||||||||||||||
Aczone® |
3.4 |
- |
- |
- |
3.4 |
37.1 |
- |
0.2 |
- |
37.3 |
(33.9) |
(90.9) |
% |
|||||||||||||||||||||||||||||||||||
Zenpep® |
- |
133.0 |
- |
- |
133.0 |
- |
108.4 |
- |
- |
108.4 |
24.6 |
22.7 |
% |
|||||||||||||||||||||||||||||||||||
Canasa®/Salofalk® |
- |
18.2 |
7.7 |
- |
25.9 |
- |
83.6 |
8.7 |
- |
92.3 |
(66.4) |
(71.9) |
% |
|||||||||||||||||||||||||||||||||||
Vraylar® |
- |
339.8 |
- |
- |
339.8 |
- |
198.6 |
- |
- |
198.6 |
141.2 |
71.1 |
% |
|||||||||||||||||||||||||||||||||||
Saphris® |
- |
64.5 |
- |
- |
64.5 |
- |
66.5 |
- |
- |
66.5 |
(2.0) |
(3.0) |
% |
|||||||||||||||||||||||||||||||||||
Viberzi® |
- |
88.0 |
0.6 |
- |
88.6 |
- |
80.8 |
0.4 |
- |
81.2 |
7.4 |
9.1 |
% |
|||||||||||||||||||||||||||||||||||
Teflaro® |
- |
70.5 |
0.2 |
- |
70.7 |
- |
64.6 |
0.6 |
- |
65.2 |
5.5 |
8.4 |
% |
|||||||||||||||||||||||||||||||||||
Namzaric® |
- |
46.0 |
- |
- |
46.0 |
- |
65.2 |
- |
- |
65.2 |
(19.2) |
(29.4) |
% |
|||||||||||||||||||||||||||||||||||
Rapaflo® |
16.3 |
- |
2.0 |
- |
18.3 |
42.5 |
- |
2.8 |
- |
45.3 |
(27.0) |
(59.6) |
% |
|||||||||||||||||||||||||||||||||||
Skin Care |
77.3 |
- |
6.4 |
- |
83.7 |
66.2 |
- |
7.9 |
- |
74.1 |
9.6 |
13.0 |
% |
|||||||||||||||||||||||||||||||||||
Kybella® /Belkyra® |
15.8 |
- |
2.2 |
- |
18.0 |
19.4 |
- |
3.7 |
- |
23.1 |
(5.1) |
(22.1) |
% |
|||||||||||||||||||||||||||||||||||
Dalvance® |
- |
32.3 |
2.2 |
- |
34.5 |
- |
29.6 |
1.3 |
- |
30.9 |
3.6 |
11.7 |
% |
|||||||||||||||||||||||||||||||||||
Avycaz® |
- |
56.4 |
- |
- |
56.4 |
- |
45.3 |
- |
- |
45.3 |
11.1 |
24.5 |
% |
|||||||||||||||||||||||||||||||||||
Liletta® |
- |
36.7 |
- |
- |
36.7 |
- |
23.6 |
- |
- |
23.6 |
13.1 |
55.5 |
% |
|||||||||||||||||||||||||||||||||||
Namenda® |
- |
15.6 |
- |
- |
15.6 |
- |
44.0 |
- |
- |
44.0 |
(28.4) |
(64.5) |
% |
|||||||||||||||||||||||||||||||||||
Armour Thyroid |
- |
106.7 |
- |
- |
106.7 |
- |
97.4 |
- |
- |
97.4 |
9.3 |
9.5 |
% |
|||||||||||||||||||||||||||||||||||
Savella® |
- |
43.0 |
- |
- |
43.0 |
- |
39.0 |
- |
- |
39.0 |
4.0 |
10.3 |
% |
|||||||||||||||||||||||||||||||||||
Other Products Revenues |
131.2 |
387.9 |
167.2 |
4.4 |
690.7 |
158.7 |
383.2 |
196.5 |
34.4 |
772.8 |
(82.1) |
(10.6) |
% |
|||||||||||||||||||||||||||||||||||
Total Net Revenues |
$ |
3,328.0 |
$ |
2,705.6 |
$ |
1,649.2 |
$ |
4.4 |
7,687.2 |
$ |
3,405.3 |
$ |
2,543.7 |
$ |
1,812.9 |
$ |
34.4 |
7,796.3 |
$ |
(109.1) |
(1.4) |
% |
||||||||||||||||||||||||||
1Botox® is comprised of the following: |
||||||||||||||||||||||||||||||||||||||||||||||||
Botox® Therapeutics |
844.6 |
- |
192.7 |
- |
1,037.3 |
797.8 |
- |
200.8 |
- |
998.6 |
38.7 |
3.9 |
% |
|||||||||||||||||||||||||||||||||||
Botox® Cosmetics |
481.9 |
- |
323.2 |
- |
805.1 |
433.2 |
- |
320.0 |
- |
753.2 |
51.9 |
6.9 |
% |
|||||||||||||||||||||||||||||||||||
The following table presents Allergan plc's Condensed Consolidated Balance Sheets as of June 30, 2019 and December 31, 2018. |
||||||||
Table 3 |
||||||||
ALLERGAN PLC |
||||||||
CONDENSED CONSOLIDATED BALANCE SHEETS |
||||||||
(Unaudited; in millions) |
||||||||
June 30 |
December 31, |
|||||||
2019 |
2018 |
|||||||
Assets |
||||||||
Cash and cash equivalents |
$ |
1,651.4 |
$ |
880.4 |
||||
Marketable securities |
322.3 |
1,026.9 |
||||||
Accounts receivable, net |
3,086.3 |
2,868.1 |
||||||
Inventories |
1,004.5 |
846.9 |
||||||
Prepaid expenses and other current assets |
2,508.3 |
819.1 |
||||||
Assets held for sale |
32.5 |
916.2 |
||||||
Property, plant and equipment, net |
1,821.0 |
1,787.0 |
||||||
Investments and other assets |
1,024.3 |
3,034.3 |
||||||
Right of use asset - operating leases |
457.9 |
- |
||||||
Product rights and other intangibles |
41,231.5 |
43,695.4 |
||||||
Goodwill |
42,340.7 |
45,913.3 |
||||||
Total assets |
$ |
95,480.7 |
$ |
101,787.6 |
||||
Liabilities & Equity |
||||||||
Current liabilities |
$ |
5,086.3 |
$ |
4,859.6 |
||||
Lease liability |
538.0 |
$ |
- |
|||||
Current and long-term debt and capital leases |
22,703.5 |
23,797.7 |
||||||
Deferred income taxes and other liabilities |
7,456.8 |
7,999.3 |
||||||
Total equity |
59,696.1 |
65,131.0 |
||||||
Total liabilities and equity |
$ |
95,480.7 |
$ |
101,787.6 |
The following table presents Allergan plc's Condensed Consolidated Statements of Cash Flows for the three and six months ended June 30, 2019 and 2018. |
||||||||||||||||
Table 4 |
||||||||||||||||
ALLERGAN PLC |
||||||||||||||||
CONSOLIDATED STATEMENTS OF CASH FLOWS |
||||||||||||||||
(Unaudited; in millions) |
||||||||||||||||
Three Months Ended June 30, |
Six Months Ended June 30, |
|||||||||||||||
2019 |
2018 |
2019 |
2018 |
|||||||||||||
Cash Flows From Operating Activities: |
||||||||||||||||
Net (loss) / income |
$ |
(1,754.9) |
$ |
(470.1) |
$ |
(4,162.2) |
$ |
(754.0) |
||||||||
Reconciliation to net cash provided by operating activities: |
||||||||||||||||
Depreciation |
48.7 |
49.1 |
96.2 |
105.2 |
||||||||||||
Amortization |
1,402.0 |
1,697.1 |
2,801.4 |
3,394.7 |
||||||||||||
Provision for inventory reserve |
64.6 |
31.2 |
83.4 |
45.4 |
||||||||||||
Share-based compensation |
59.5 |
54.9 |
111.8 |
127.4 |
||||||||||||
Deferred income tax benefit |
63.3 |
(333.2) |
(166.4) |
(1,359.6) |
||||||||||||
In-process research and development impairments |
436.0 |
276.0 |
436.0 |
798.0 |
||||||||||||
Goodwill and other impairments and asset sales, net |
1,215.2 |
259.6 |
3,677.0 |
272.7 |
||||||||||||
Gain on forward sale of Teva shares |
- |
(138.6) |
- |
(60.9) |
||||||||||||
Gain on sale of business |
- |
(53.0) |
- |
(53.0) |
||||||||||||
Non-cash extinguishment of debt |
(0.1) |
4.0 |
0.2 |
4.0 |
||||||||||||
Cash charge related to extinguishment of debt |
- |
(13.1) |
- |
(13.1) |
||||||||||||
Amortization of deferred financing costs |
4.5 |
5.6 |
9.1 |
11.9 |
||||||||||||
Non-cash lease expense |
37.9 |
- |
68.0 |
- |
||||||||||||
Contingent consideration adjustments, |
28.1 |
(107.1) |
46.8 |
(101.8) |
||||||||||||
Other, net |
(9.0) |
(6.8) |
(19.3) |
(0.3) |
||||||||||||
Changes in assets and liabilities (net of effects |
||||||||||||||||
Decrease / (increase) in accounts receivable, net |
(353.0) |
(168.8) |
(220.6) |
90.3 |
||||||||||||
Decrease / (increase) in inventories |
(51.0) |
(60.6) |
(179.3) |
(113.3) |
||||||||||||
Decrease / (increase) in prepaid expenses |
(12.3) |
39.9 |
23.9 |
39.3 |
||||||||||||
Increase / (decrease) in accounts payable |
361.4 |
191.2 |
161.6 |
(40.4) |
||||||||||||
Increase / (decrease) in income and other |
(104.2) |
28.8 |
(44.2) |
365.4 |
||||||||||||
Increase / (decrease) in other assets and liabilities |
(26.4) |
(45.9) |
(79.1) |
(59.4) |
||||||||||||
Net cash provided by operating activities |
1,410.3 |
1,240.2 |
2,644.3 |
2,698.5 |
||||||||||||
Cash Flows From Investing Activities: |
||||||||||||||||
Additions to property, plant and equipment |
(87.5) |
(60.1) |
(152.3) |
(106.5) |
||||||||||||
Additions to product rights and other intangibles |
(38.5) |
- |
(46.0) |
- |
||||||||||||
Additions to investments |
(200.0) |
- |
(738.2) |
(1,455.9) |
||||||||||||
Proceeds from sale of investments and other assets |
892.9 |
761.8 |
1,462.0 |
5,651.3 |
||||||||||||
Payments to settle Teva related matters |
- |
- |
- |
(466.0) |
||||||||||||
Proceeds from sales of property, plant and equipment |
0.5 |
0.4 |
17.7 |
11.5 |
||||||||||||
Acquisitions of businesses, net of cash acquired |
- |
- |
(80.6) |
- |
||||||||||||
Net cash (used in) investing activities |
567.4 |
702.1 |
462.6 |
3,634.4 |
||||||||||||
Cash Flows From Financing Activities: |
||||||||||||||||
Proceeds from borrowings on long-term indebtedness, including credit facility |
3.3 |
- |
3.3 |
709.0 |
||||||||||||
Proceeds from Forward Sale of Teva securities |
- |
93.2 |
- |
465.5 |
||||||||||||
Payments on debt, including capital lease obligations |
(879.7) |
(1,031.6) |
(1,039.1) |
(5,353.7) |
||||||||||||
Proceeds from stock plans |
13.9 |
33.7 |
23.6 |
69.2 |
||||||||||||
Other financing, including contingent consideration |
(2.1) |
(1.3) |
(4.1) |
(10.6) |
||||||||||||
Payments to settle Teva related matters |
- |
- |
- |
(234.0) |
||||||||||||
Repurchase of ordinary shares |
(4.3) |
(132.5) |
(833.5) |
(1,572.1) |
||||||||||||
Dividends |
(242.7) |
(244.2) |
(488.8) |
(563.7) |
||||||||||||
Net cash (used in) financing activities |
(1,111.6) |
(1,282.7) |
(2,338.6) |
(6,490.4) |
||||||||||||
Effect of currency exchange rate changes on cash and cash equivalents |
(3.2) |
20.3 |
2.7 |
15.0 |
||||||||||||
Net increase / (decrease) in cash and cash equivalents |
862.9 |
679.9 |
771.0 |
(142.5) |
||||||||||||
Cash and cash equivalents at beginning of period |
788.5 |
994.8 |
880.4 |
1,817.2 |
||||||||||||
Cash and cash equivalents at end of period |
$ |
1,651.4 |
$ |
1,674.7 |
$ |
1,651.4 |
$ |
1,674.7 |
Non-GAAP performance net income per share is used by management as one of the primary metrics in evaluating the Company's performance. We believe that Non-GAAP performance net income per share enhances the comparability of our results between periods and provides additional information and transparency to investors on adjustments and other items that are not indicative of the Company's current and future operating performance. These are the financial measures used by our management team to evaluate our operating performance and make day to day operating decisions. We define non-GAAP adjustments to the reported GAAP measures as GAAP results adjusted for the following net of tax: (i) amortization expenses, (ii) global supply chain and operational excellence initiatives or other restructurings of a similar nature, (iii) acquisition, divestiture, integration and licensing charges, (iv) accretion and fair market value adjustments on contingent liabilities, (v) impairment/asset sales and related costs, including the exclusion of discontinued operations, (vi) legal settlements and (vii) other unusual charges or expenses. Non-GAAP performance net income per share is not, and should not be viewed as, a substitute for reported GAAP continuing operations loss per share. The Company has consistently excluded amortization of all intangible assets, including the product rights that generate a significant portion of our ongoing revenue. The Company's total accumulated amortization, including impairments of currently marketed products, related to our intangible assets as of June 30, 2019 and December 31, 2018 was $36.2 billion and $32.3 billion, respectively, and is expected to continue to be a material non-GAAP adjustment. The following table presents Allergan plc's GAAP to Non-GAAP adjustments for the three and six months ended June 30, 2019 and 2018: |
||||||||||||||||||||||||||||||||||||||||
Table 5 |
||||||||||||||||||||||||||||||||||||||||
ALLERGAN PLC |
||||||||||||||||||||||||||||||||||||||||
GAAP TO NON-GAAP ADJUSTMENTS |
||||||||||||||||||||||||||||||||||||||||
(Unaudited; in millions) |
||||||||||||||||||||||||||||||||||||||||
Three Months Ended June 30, 2019 |
||||||||||||||||||||||||||||||||||||||||
Net Revenue |
COGS |
Research & Development |
Selling & Marketing |
General & Administrative |
Amortization |
Asset sales & |
Interest expense, net |
Other income (expense) |
Income taxes |
|||||||||||||||||||||||||||||||
GAAP |
$ |
4,090.1 |
$ |
652.3 |
$ |
450.0 |
$ |
873.3 |
$ |
324.2 |
$ |
1,402.0 |
$ |
1,651.2 |
$ |
(185.7) |
$ |
(4.7) |
$ |
301.6 |
||||||||||||||||||||
Purchase accounting impact on stock-based compensation for |
- |
(0.2) |
(0.3) |
(0.7) |
(0.2) |
- |
- |
- |
- |
- |
||||||||||||||||||||||||||||||
Non-acquisition related severance and restructuring |
- |
(0.3) |
- |
(0.9) |
(2.1) |
- |
- |
- |
- |
- |
||||||||||||||||||||||||||||||
Costs associated with disposed businesses |
- |
- |
- |
- |
(0.1) |
- |
- |
- |
- |
- |
||||||||||||||||||||||||||||||
Integration charges of acquired businesses |
- |
- |
(0.4) |
(0.1) |
(4.0) |
- |
- |
- |
- |
- |
||||||||||||||||||||||||||||||
Costs associated with the Abbvie transaction |
- |
- |
- |
- |
(19.5) |
- |
- |
- |
- |
- |
||||||||||||||||||||||||||||||
Accretion and fair-value adjustments to contingent |
- |
(25.8) |
(2.3) |
- |
- |
- |
- |
- |
- |
- |
||||||||||||||||||||||||||||||
Non-cash amortization of debt premium recognized in |
- |
- |
- |
- |
- |
- |
- |
(5.5) |
- |
- |
||||||||||||||||||||||||||||||
Impairment of goodwill |
- |
- |
- |
- |
- |
- |
(1,085.2) |
- |
- |
- |
||||||||||||||||||||||||||||||
Impairment of Anti-Infective assets previously held for sale |
- |
- |
- |
- |
- |
- |
(129.6) |
- |
- |
- |
||||||||||||||||||||||||||||||
Impairment of IPR&D products acquired in the Allergan |
- |
- |
- |
- |
- |
- |
(182.0) |
- |
- |
- |
||||||||||||||||||||||||||||||
Impairment of IPR&D product acquired in the Vitae Acquisition |
- |
- |
- |
- |
- |
- |
(78.0) |
- |
- |
- |
||||||||||||||||||||||||||||||
Impairment of IPR&D products acquired in the Tobira |
- |
- |
- |
- |
- |
- |
(176.0) |
- |
- |
- |
||||||||||||||||||||||||||||||
Asset sales and impairments, other |
- |
- |
- |
- |
- |
- |
(0.4) |
- |
- |
- |
||||||||||||||||||||||||||||||
Litigation settlement related charges |
- |
- |
- |
- |
(7.8) |
- |
- |
- |
- |
- |
||||||||||||||||||||||||||||||
Other adjustments |
- |
(0.1) |
- |
- |
0.7 |
(1,402.0) |
- |
- |
- |
- |
||||||||||||||||||||||||||||||
Income taxes on pre-tax adjustments |
- |
- |
- |
- |
- |
- |
- |
- |
- |
288.1 |
||||||||||||||||||||||||||||||
Discrete income tax events |
- |
- |
- |
- |
- |
- |
- |
- |
- |
(377.6) |
||||||||||||||||||||||||||||||
Non-GAAP Adjusted |
$ |
4,090.1 |
$ |
625.9 |
$ |
447.0 |
$ |
871.6 |
$ |
291.2 |
$ |
- |
$ |
- |
$ |
(191.2) |
$ |
(4.7) |
$ |
212.1 |
||||||||||||||||||||
Three Months Ended June 30, 2018 |
||||||||||||||||||||||||||||||||||||||||
Net Revenue |
COGS |
Research & |
Selling & |
General & |
Amortization |
Asset sales & |
Interest expense, net |
Other income (expense) |
Income taxes |
|||||||||||||||||||||||||||||||
GAAP |
$ |
4,124.2 |
$ |
481.8 |
$ |
689.2 |
$ |
853.4 |
$ |
334.1 |
$ |
1,697.1 |
$ |
535.6 |
$ |
(223.7) |
$ |
215.4 |
$ |
(5.2) |
||||||||||||||||||||
Purchase accounting impact on stock-based compensation for |
- |
(0.4) |
(0.8) |
(1.7) |
(0.5) |
- |
- |
- |
- |
- |
||||||||||||||||||||||||||||||
Severance due to integration of acquired entities |
- |
- |
- |
- |
(0.3) |
- |
- |
- |
- |
- |
||||||||||||||||||||||||||||||
Non-acquisition related severance and restructuring |
- |
(9.3) |
(0.3) |
(6.9) |
3.0 |
- |
- |
- |
- |
- |
||||||||||||||||||||||||||||||
Costs associated with disposed businesses |
- |
(1.0) |
- |
- |
(0.7) |
- |
- |
- |
- |
- |
||||||||||||||||||||||||||||||
Integration charges of acquired businesses |
- |
- |
(0.4) |
(0.5) |
(13.9) |
- |
- |
- |
- |
- |
||||||||||||||||||||||||||||||
Milestones and upfront expenses for asset acquisitions |
||||||||||||||||||||||||||||||||||||||||
Elastagen Pty Ltd |
- |
- |
(96.1) |
- |
- |
- |
- |
- |
- |
- |
||||||||||||||||||||||||||||||
AstraZeneca plc |
- |
- |
(90.0) |
- |
- |
- |
- |
- |
- |
- |
||||||||||||||||||||||||||||||
Merck & Co. |
- |
- |
(85.0) |
- |
- |
- |
- |
- |
- |
- |
||||||||||||||||||||||||||||||
Other |
- |
- |
(6.2) |
- |
- |
- |
- |
- |
- |
- |
||||||||||||||||||||||||||||||
Accretion and fair-value adjustments to contingent |
- |
128.8 |
(21.7) |
- |
- |
- |
- |
- |
- |
- |
||||||||||||||||||||||||||||||
Non-cash amortization of debt premium recognized in |
- |
- |
- |
- |
- |
- |
- |
(5.4) |
- |
- |
||||||||||||||||||||||||||||||
Impairment of IPR&D products acquired in the Allergan |
- |
- |
- |
- |
- |
- |
(236.0) |
- |
- |
- |
||||||||||||||||||||||||||||||
Impairment of IPR&D products acquired in the Vitae Acquisition |
- |
- |
- |
- |
- |
- |
(40.0) |
- |
- |
- |
||||||||||||||||||||||||||||||
Impairment of assets held for sale |
- |
- |
- |
- |
- |
- |
(252.0) |
- |
- |
- |
||||||||||||||||||||||||||||||
Asset sales and impairments, other |
- |
- |
- |
- |
- |
- |
(7.6) |
- |
- |
- |
||||||||||||||||||||||||||||||
Gain on Teva shares |
- |
- |
- |
- |
- |
- |
- |
- |
(138.3) |
- |
||||||||||||||||||||||||||||||
Milestone component of ongoing intellectual property |
(25.0) |
- |
- |
- |
- |
- |
- |
- |
- |
- |
||||||||||||||||||||||||||||||
Gain on the sale of divestiture |
- |
- |
- |
- |
- |
- |
- |
- |
(53.0) |
- |
||||||||||||||||||||||||||||||
Gain on bond repurchases |
- |
- |
- |
- |
- |
- |
- |
- |
(9.1) |
- |
||||||||||||||||||||||||||||||
Litigation settlement related charges |
- |
- |
- |
- |
(29.0) |
- |
- |
- |
- |
- |
||||||||||||||||||||||||||||||
Other adjustments |
- |
0.1 |
0.2 |
- |
(2.6) |
(1,697.1) |
- |
- |
0.1 |
- |
||||||||||||||||||||||||||||||
Income taxes on pre-tax adjustments |
- |
- |
- |
- |
- |
- |
- |
- |
- |
315.3 |
||||||||||||||||||||||||||||||
Discrete income tax events |
- |
- |
- |
- |
- |
- |
- |
- |
- |
(58.0) |
||||||||||||||||||||||||||||||
Non-GAAP Adjusted |
$ |
4,099.2 |
$ |
600.0 |
$ |
388.9 |
$ |
844.3 |
$ |
290.1 |
$ |
- |
$ |
- |
$ |
(229.1) |
$ |
15.1 |
$ |
252.1 |
||||||||||||||||||||
The non-GAAP income tax expense is determined based on our pre-tax income, adjusted for non-GAAP items on a jurisdiction by jurisdiction basis. The non-GAAP effective tax rate in the three months ended June 30, 2019 was impacted by U.S. income taxed at rates higher than the Irish statutory rate, partially offset by income earned in jurisdictions with tax rates lower than the Irish statutory rate.
The non-GAAP effective tax rate for the three months ended June 30, 2019 excludes a net discrete tax detriment of $377.6 million related to a change in a valuation allowance and uncertain tax positions offset by the tax effects of intangible asset impairments and U.S. capital losses. |
||||||||||||||||||||||||||||||||||||||||
Six Months Ended June 30, 2019 |
||||||||||||||||||||||||||||||||||||||||
Net Revenue |
COGS |
Research & Development |
Selling & Marketing |
General & Administrative |
Amortization |
Asset sales & |
Interest expense, net |
Other income (expense) |
Income taxes |
|||||||||||||||||||||||||||||||
GAAP |
$ |
7,687.2 |
$ |
1,150.1 |
$ |
885.0 |
$ |
1,677.3 |
$ |
632.5 |
$ |
2,801.4 |
$ |
4,113.0 |
$ |
(366.2) |
$ |
9.1 |
$ |
233.0 |
||||||||||||||||||||
Purchase accounting impact on stock-based compensation for |
- |
(0.5) |
(0.7) |
(1.6) |
(0.5) |
- |
- |
- |
- |
- |
||||||||||||||||||||||||||||||
Severance due to integration of acquired entities |
- |
- |
- |
- |
(0.8) |
- |
- |
- |
- |
- |
||||||||||||||||||||||||||||||
Non-acquisition related severance and restructuring |
- |
(4.9) |
- |
0.9 |
(2.2) |
- |
- |
- |
- |
- |
||||||||||||||||||||||||||||||
Costs associated with disposed businesses |
- |
- |
- |
- |
(0.3) |
- |
- |
- |
- |
- |
||||||||||||||||||||||||||||||
Integration charges of acquired businesses |
- |
- |
(0.5) |
(0.1) |
(8.3) |
- |
- |
- |
- |
- |
||||||||||||||||||||||||||||||
Costs associated with the Abbvie transaction |
- |
- |
- |
- |
(19.5) |
- |
- |
- |
- |
- |
||||||||||||||||||||||||||||||
Milestones and upfront expenses for asset acquisitions |
||||||||||||||||||||||||||||||||||||||||
Akarna Therapeutics, Ltd |
- |
- |
(10.0) |
- |
- |
- |
- |
- |
- |
- |
||||||||||||||||||||||||||||||
Other |
- |
- |
(24.1) |
- |
- |
- |
- |
- |
- |
- |
||||||||||||||||||||||||||||||
Accretion and fair-value adjustments to contingent |
- |
(42.0) |
(4.8) |
- |
- |
- |
- |
- |
- |
- |
||||||||||||||||||||||||||||||
Non-cash amortization of debt premium recognized in |
- |
- |
- |
- |
- |
- |
- |
(11.0) |
- |
- |
||||||||||||||||||||||||||||||
Impairment of goodwill |
- |
- |
- |
- |
- |
- |
(3,552.2) |
- |
- |
- |
||||||||||||||||||||||||||||||
Impairment of Anti-Infective assets previously held for sale |
(129.6) |
|||||||||||||||||||||||||||||||||||||||
Impairment of IPR&D products acquired in the Allergan |
(182.0) |
|||||||||||||||||||||||||||||||||||||||
Impairment of IPR&D product acquired in the Vitae Acquisition |
(78.0) |
|||||||||||||||||||||||||||||||||||||||
Impairment of IPR&D products acquired in the Tobira |
(176.0) |
|||||||||||||||||||||||||||||||||||||||
Asset sales and impairments, other |
- |
- |
- |
- |
- |
- |
4.8 |
- |
- |
- |
||||||||||||||||||||||||||||||
Litigation settlement related charges |
- |
- |
- |
- |
(18.2) |
- |
- |
- |
- |
- |
||||||||||||||||||||||||||||||
Other adjustments |
- |
(0.1) |
- |
- |
(0.2) |
(2,801.4) |
- |
- |
(0.3) |
- |
||||||||||||||||||||||||||||||
Income taxes on pre-tax adjustments |
- |
- |
- |
- |
- |
- |
- |
- |
- |
474.7 |
||||||||||||||||||||||||||||||
Discrete income tax events |
- |
- |
- |
- |
- |
- |
- |
- |
- |
(309.2) |
||||||||||||||||||||||||||||||
Non-GAAP Adjusted |
$ |
7,687.2 |
$ |
1,102.6 |
$ |
844.9 |
$ |
1,676.5 |
$ |
582.5 |
$ |
- |
$ |
- |
$ |
(377.2) |
$ |
8.8 |
$ |
398.5 |
||||||||||||||||||||
Six Months Ended June 30, 2018 |
||||||||||||||||||||||||||||||||||||||||
Net Revenue |
COGS |
Research & |
Selling & |
General & |
Amortization |
Asset sales & |
Interest expense, net |
Other income (expense) |
Income taxes |
|||||||||||||||||||||||||||||||
GAAP |
$ |
7,796.3 |
$ |
1,004.6 |
$ |
1,163.9 |
$ |
1,653.4 |
$ |
630.0 |
$ |
3,394.7 |
$ |
1,070.7 |
$ |
(457.0) |
$ |
136.6 |
$ |
(687.4) |
||||||||||||||||||||
Purchase accounting impact on stock-based compensation for |
- |
(1.5) |
(3.6) |
(6.0) |
(2.1) |
- |
- |
- |
- |
- |
||||||||||||||||||||||||||||||
Severance due to integration of acquired entities |
- |
- |
- |
(0.7) |
(0.8) |
- |
- |
- |
- |
- |
||||||||||||||||||||||||||||||
Non-acquisition related severance and restructuring |
- |
(21.9) |
(0.9) |
(17.2) |
(4.3) |
- |
(13.6) |
- |
- |
- |
||||||||||||||||||||||||||||||
Costs associated with disposed businesses |
- |
(1.5) |
- |
- |
(3.3) |
- |
- |
- |
- |
- |
||||||||||||||||||||||||||||||
Integration charges of acquired businesses |
- |
- |
(0.6) |
(0.7) |
(24.6) |
- |
- |
- |
- |
- |
||||||||||||||||||||||||||||||
Milestones and upfront expenses for asset acquisitions |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
||||||||||||||||||||||||||||||
Elastagen Pty Ltd |
- |
- |
(96.1) |
- |
- |
- |
- |
- |
- |
- |
||||||||||||||||||||||||||||||
AstraZeneca plc |
- |
- |
(90.0) |
- |
- |
- |
- |
- |
- |
- |
||||||||||||||||||||||||||||||
Merck & Co. |
- |
- |
(85.0) |
- |
- |
- |
- |
- |
- |
- |
||||||||||||||||||||||||||||||
Chase Pharmaceuticals Corporation |
- |
- |
(75.0) |
- |
- |
- |
- |
- |
- |
- |
||||||||||||||||||||||||||||||
Repros Therapeutics, Inc. |
- |
- |
(33.2) |
- |
- |
- |
- |
- |
- |
- |
||||||||||||||||||||||||||||||
Other |
- |
- |
(11.4) |
- |
- |
- |
- |
- |
- |
- |
||||||||||||||||||||||||||||||
Accretion and fair-value adjustments to contingent |
- |
125.4 |
(23.6) |
- |
- |
- |
- |
- |
- |
- |
||||||||||||||||||||||||||||||
Non-cash amortization of debt premium recognized in |
- |
- |
- |
- |
- |
- |
- |
(10.2) |
- |
- |
||||||||||||||||||||||||||||||
Impairment of IPR&D products acquired in the Allergan |
- |
- |
- |
- |
- |
- |
(236.0) |
- |
- |
- |
||||||||||||||||||||||||||||||
Impairment of IPR&D products acquired in the Vitae |
- |
- |
- |
- |
- |
- |
(40.0) |
- |
- |
- |
||||||||||||||||||||||||||||||
Impairment of assets held for sale |
- |
- |
- |
- |
- |
- |
(252.0) |
- |
- |
- |
||||||||||||||||||||||||||||||
Impairment of RORgt IPR&D product |
- |
- |
- |
- |
- |
- |
(522.0) |
- |
- |
- |
||||||||||||||||||||||||||||||
Asset sales and impairments, other |
- |
- |
- |
- |
- |
- |
(7.1) |
- |
- |
- |
||||||||||||||||||||||||||||||
Gain on Teva securities |
- |
- |
- |
- |
- |
- |
- |
- |
(60.6) |
- |
||||||||||||||||||||||||||||||
Milestone component of ongoing intellectual property |
(25.0) |
- |
- |
- |
- |
- |
- |
- |
- |
- |
||||||||||||||||||||||||||||||
Gain on the sale of divestiture |
- |
- |
- |
- |
- |
- |
- |
- |
(53.0) |
- |
||||||||||||||||||||||||||||||
Gain on bond repurchases |
- |
- |
- |
- |
- |
- |
- |
- |
(9.1) |
- |
||||||||||||||||||||||||||||||
Litigation settlement related charges |
- |
- |
- |
- |
(39.3) |
- |
- |
- |
- |
- |
||||||||||||||||||||||||||||||
Other adjustments |
- |
0.1 |
0.2 |
- |
(1.3) |
(3,394.7) |
- |
- |
0.1 |
- |
||||||||||||||||||||||||||||||
Income taxes on pre-tax adjustments |
- |
- |
- |
- |
- |
- |
- |
- |
- |
753.1 |
||||||||||||||||||||||||||||||
Discrete income tax events |
- |
- |
- |
- |
- |
- |
- |
- |
- |
401.6 |
||||||||||||||||||||||||||||||
Non-GAAP Adjusted |
$ |
7,771.3 |
$ |
1,105.2 |
$ |
744.7 |
$ |
1,628.8 |
$ |
554.3 |
$ |
- |
$ |
- |
$ |
(467.2) |
$ |
14.0 |
$ |
467.3 |
||||||||||||||||||||
The non-GAAP income tax expense is determined based on our pre-tax income, adjusted for non-GAAP items on a jurisdiction by jurisdiction basis. The non-GAAP effective tax rate in the six months ended June 30, 2019 was impacted by U.S. income taxed at rates higher than the Irish statutory rate, partially offset by income earned in jurisdictions with tax rates lower than the Irish statutory rate.
The non-GAAP effective tax rate for the six months ended June 30, 2019 excludes a net discrete tax detriment of $309.2 million related to a change in a valuation allowance and uncertain tax positions offset by the tax effects of intangible asset impairments and U.S. capital losses. |
||||||||||||||||||||||||||||||||||||||||
The following table presents a reconciliation of Allergan plc's reported net income / (loss) from continuing operations attributable to shareholders and diluted earnings per share to non-GAAP performance net income and non-GAAP performance net income per share for the three and six months ended June 30, 2019 and 2018: |
||||||||||||||||
Table 6 |
||||||||||||||||
ALLERGAN PLC |
||||||||||||||||
RECONCILIATION TABLE |
||||||||||||||||
(Unaudited; in millions except per share amounts) |
||||||||||||||||
Three Months Ended |
Six Months Ended |
|||||||||||||||
June 30, |
June 30, |
|||||||||||||||
2019 |
2018 |
2019 |
2018 |
|||||||||||||
GAAP to Non-GAAP Performance net income calculation |
||||||||||||||||
GAAP (loss) / income from continuing operations |
$ |
(1,759.0) |
$ |
(472.5) |
$ |
(4,167.0) |
$ |
(758.6) |
||||||||
Adjusted for: |
||||||||||||||||
Amortization |
1,402.0 |
1,697.1 |
2,801.4 |
3,394.7 |
||||||||||||
Acquisition, divestiture and licensing (income) / |
19.4 |
103.3 |
55.9 |
313.5 |
||||||||||||
Accretion and fair-value adjustments to contingent |
28.1 |
(107.1) |
46.8 |
(101.8) |
||||||||||||
Goodwill and other impairments and asset sales, net |
1,651.2 |
535.6 |
4,113.0 |
1,070.7 |
||||||||||||
Other |
- |
(34.2) |
- |
(34.2) |
||||||||||||
Non-acquisition restructurings, including Global Supply |
3.3 |
13.5 |
6.2 |
44.3 |
||||||||||||
Legal settlements |
7.8 |
29.0 |
18.2 |
39.3 |
||||||||||||
Income taxes on items above and other discrete |
89.5 |
(257.3) |
(165.5) |
(1,154.7) |
||||||||||||
Non-GAAP performance net income attributable to |
$ |
1,442.3 |
$ |
1,507.4 |
$ |
2,709.0 |
$ |
2,813.2 |
||||||||
Diluted earnings per share |
||||||||||||||||
Diluted (loss) / income per share from continuing |
$ |
(5.37) |
$ |
(1.39) |
$ |
(12.63) |
$ |
(2.25) |
||||||||
Non-GAAP performance net income per share attributable |
$ |
4.38 |
$ |
4.42 |
$ |
8.17 |
$ |
8.16 |
||||||||
Basic weighted average ordinary shares outstanding |
327.8 |
339.1 |
329.9 |
336.9 |
||||||||||||
Effect of dilutive securities: |
||||||||||||||||
Dilutive shares |
1.6 |
2.2 |
1.8 |
8.0 |
||||||||||||
Diluted weighted average ordinary shares outstanding |
329.4 |
341.3 |
331.7 |
344.9 |
||||||||||||
We define adjusted EBITDA as an amount equal to consolidated net income / (loss) from continuing operations attributable to shareholders for such period adjusted for the following: (i) interest expense, (ii) interest income, (iii) (benefit) for income taxes, (iv) depreciation and amortization expenses, (v) stock-based compensation expense, (vi) asset impairment charges and losses / (gains) and expenses associated with the sale of assets, including the exclusion of discontinued operations, (vii) business restructuring charges associated with Allergan's global supply chain and operational excellence initiatives or other restructurings of a similar nature, (viii) costs and charges associated with the acquisition and divestitures of businesses and assets including, but not limited to, milestone payments, integration charges, other charges associated with the revaluation of assets or liabilities and charges associated with the revaluation of acquisition related contingent liabilities that are based in whole or in part on future estimated cash flows, (ix) litigation charges and settlements and (x) other unusual charges or expenses. We define non-GAAP adjusted operating income as adjusted EBITDA including depreciation and certain stock-based compensation charges and excluding dividend income and fair value accounting results included within other income (expense), net.
The following table presents a reconciliation of Allergan plc's reported net income / (loss) from continuing operations attributable to shareholders for the three and six months ended June 30, 2019 and 2018 to adjusted EBITDA and Non-GAAP operating income: |
||||||||||||||||
Table 7 |
||||||||||||||||
ALLERGAN PLC |
||||||||||||||||
ADJUSTED EBITDA and NON-GAAP OPERATING INCOME, RECONCILIATION TABLE |
||||||||||||||||
(Unaudited; in millions) |
||||||||||||||||
Three Months Ended |
Six Months Ended |
|||||||||||||||
June 30, |
June 30, |
|||||||||||||||
2019 |
2018 |
2019 |
2018 |
|||||||||||||
GAAP (loss) / income from continuing operations attributable to |
$ |
(1,759.0) |
$ |
(472.5) |
$ |
(4,167.0) |
$ |
(758.6) |
||||||||
Plus: |
||||||||||||||||
Interest expense |
195.4 |
230.0 |
397.2 |
480.6 |
||||||||||||
Interest income |
(9.7) |
(6.3) |
(31.0) |
(23.6) |
||||||||||||
(Benefit) for income taxes |
301.6 |
(5.2) |
233.0 |
(687.4) |
||||||||||||
Depreciation |
48.7 |
49.1 |
96.2 |
105.2 |
||||||||||||
Amortization |
1,402.0 |
1,697.1 |
2,801.4 |
3,394.7 |
||||||||||||
EBITDA |
$ |
179.0 |
$ |
1,492.2 |
$ |
(670.2) |
$ |
2,510.9 |
||||||||
Adjusted for: |
||||||||||||||||
Acquisition, divestiture and licensing charges |
23.5 |
105.3 |
63.6 |
302.3 |
||||||||||||
Goodwill and other impairments and asset sales, net and |
1,651.2 |
535.6 |
4,113.0 |
1,070.7 |
||||||||||||
Other |
- |
(34.2) |
- |
(34.2) |
||||||||||||
Non-acquisition restructurings, including Global Supply Chain |
3.3 |
10.5 |
6.2 |
41.3 |
||||||||||||
Legal settlements |
7.8 |
29.0 |
18.2 |
39.3 |
||||||||||||
Accretion and fair-value adjustments to contingent |
28.1 |
(107.1) |
46.8 |
(101.8) |
||||||||||||
Share-based compensation including cash settlements |
59.5 |
54.9 |
111.8 |
127.4 |
||||||||||||
Adjusted EBITDA |
$ |
1,952.4 |
$ |
2,086.2 |
$ |
3,689.4 |
$ |
3,955.9 |
||||||||
Adjusted for: |
||||||||||||||||
Depreciation |
(48.7) |
(46.1) |
(96.2) |
(102.2) |
||||||||||||
Other income (expense) related to fair value accounting |
4.7 |
(14.8) |
(8.8) |
(14.8) |
||||||||||||
Share-based compensation not related to restructuring |
(58.1) |
(51.5) |
(108.5) |
(106.0) |
||||||||||||
Non-GAAP Operating Income |
$ |
1,850.3 |
$ |
1,973.8 |
$ |
3,475.9 |
$ |
3,732.9 |
The following table details Allergan plc's segment contribution reconciled to the non-GAAP contribution for the same financial statement line items for the three and six months ended June 30, 2019 and 2018. |
||||||||||||||||||||||||||||||||||||||||
Table 8 |
||||||||||||||||||||||||||||||||||||||||
ALLERGAN PLC |
||||||||||||||||||||||||||||||||||||||||
Segment Contribution to Non-GAAP Allergan plc Contribution |
||||||||||||||||||||||||||||||||||||||||
(Unaudited; $ in millions) |
||||||||||||||||||||||||||||||||||||||||
Three Months Ended June 30, 2019 |
Three Months Ended June 30, 2018 |
|||||||||||||||||||||||||||||||||||||||
US Specialized Therapeutics Segment |
US General Medicine Segment |
International Segment |
Corporate |
Total |
US Specialized Therapeutics Segment |
US General Medicine Segment |
International Segment |
Corporate |
Total |
|||||||||||||||||||||||||||||||
Net revenues |
$ |
1,785.1 |
$ |
1,455.7 |
$ |
847.7 |
$ |
1.6 |
$ |
4,090.1 |
$ |
1,826.7 |
$ |
1,320.0 |
$ |
948.9 |
$ |
3.6 |
$ |
4,099.2 |
||||||||||||||||||||
Operating expenses: |
||||||||||||||||||||||||||||||||||||||||
Cost of sales(1) |
151.0 |
231.3 |
145.6 |
98.0 |
625.9 |
148.7 |
201.8 |
139.4 |
110.1 |
600.0 |
||||||||||||||||||||||||||||||
Selling and marketing |
368.0 |
250.1 |
253.6 |
(0.1) |
871.6 |
343.3 |
254.8 |
246.2 |
- |
844.3 |
||||||||||||||||||||||||||||||
General and administrative |
37.6 |
30.4 |
28.4 |
194.8 |
291.2 |
48.1 |
34.7 |
33.9 |
173.4 |
290.1 |
||||||||||||||||||||||||||||||
Segment contribution |
$ |
1,228.5 |
$ |
943.9 |
$ |
420.1 |
$ |
(291.1) |
$ |
2,301.4 |
$ |
1,286.6 |
$ |
828.7 |
$ |
529.4 |
$ |
(279.9) |
$ |
2,364.8 |
||||||||||||||||||||
Segment margin |
68.8 |
% |
64.8 |
% |
49.6 |
% |
n.m. |
56.3 |
% |
70.4 |
% |
62.8 |
% |
55.8 |
% |
n.m. |
57.7 |
% |
||||||||||||||||||||||
Segment gross margin(2) |
91.5 |
% |
84.1 |
% |
82.8 |
% |
n.m. |
84.7 |
% |
91.9 |
% |
84.7 |
% |
85.3 |
% |
n.m. |
85.4 |
% |
||||||||||||||||||||||
(1) Excludes amortization and impairment of acquired intangibles including product rights. |
||||||||||||||||||||||||||||||||||||||||
(2) Defined as net revenues less segment related cost of sales as a percentage of net revenues. |
||||||||||||||||||||||||||||||||||||||||
Six Months Ended June 30, 2019 |
Six Months Ended June 30, 2018 |
|||||||||||||||||||||||||||||||||||||||
US Specialized Therapeutics Segment |
US General Medicine Segment |
International Segment |
Corporate |
Total |
US Specialized Therapeutics Segment |
US General Medicine Segment |
International Segment |
Corporate |
Total |
|||||||||||||||||||||||||||||||
Net revenues |
$ |
3,328.0 |
$ |
2,705.6 |
$ |
1,649.2 |
$ |
4.4 |
$ |
7,687.2 |
$ |
3,405.3 |
$ |
2,543.7 |
$ |
1,812.9 |
$ |
9.4 |
$ |
7,771.3 |
||||||||||||||||||||
Operating expenses: |
||||||||||||||||||||||||||||||||||||||||
Cost of sales(1) |
271.1 |
421.8 |
255.3 |
154.4 |
1,102.6 |
282.9 |
384.4 |
260.3 |
177.6 |
1,105.2 |
||||||||||||||||||||||||||||||
Selling and marketing |
724.8 |
460.6 |
491.2 |
(0.1) |
1,676.5 |
656.5 |
480.3 |
491.9 |
0.1 |
1,628.8 |
||||||||||||||||||||||||||||||
General and administrative |
92.2 |
74.2 |
54.1 |
362.0 |
582.5 |
98.3 |
73.6 |
65.3 |
317.1 |
554.3 |
||||||||||||||||||||||||||||||
Segment contribution |
$ |
2,239.9 |
$ |
1,749.0 |
$ |
848.6 |
$ |
(511.9) |
$ |
4,325.6 |
$ |
2,367.6 |
$ |
1,605.4 |
$ |
995.4 |
$ |
(485.4) |
$ |
4,483.0 |
||||||||||||||||||||
Segment margin |
67.3 |
% |
64.6 |
% |
51.5 |
% |
n.m. |
56.3 |
% |
69.5 |
% |
63.1 |
% |
54.9 |
% |
n.m. |
57.7 |
% |
||||||||||||||||||||||
Segment gross margin(2) |
91.9 |
% |
84.4 |
% |
84.5 |
% |
n.m. |
85.7 |
% |
91.7 |
% |
84.9 |
% |
85.6 |
% |
n.m. |
85.8 |
% |
||||||||||||||||||||||
(1) Excludes amortization and impairment of acquired intangibles including product rights. |
||||||||||||||||||||||||||||||||||||||||
(2) Defined as net revenues less segment related cost of sales as a percentage of net revenues. |
||||||||||||||||||||||||||||||||||||||||
The following table details Allergan plc's product revenue for significant promoted products within the US Specialized Therapeutics segment for the three and six months ended June 30, 2019 and 2018. |
||||||||||||||||
Table 9 |
||||||||||||||||
ALLERGAN PLC |
||||||||||||||||
US Specialized Therapeutics Product Revenue |
||||||||||||||||
(Unaudited; in millions) |
||||||||||||||||
Three Months Ended June 30, |
Change |
|||||||||||||||
2019 |
2018 |
Dollars |
% |
|||||||||||||
Total Eye Care |
$ |
572.0 |
$ |
587.0 |
$ |
(15.0) |
(2.6) |
% |
||||||||
Restasis® |
310.9 |
318.2 |
(7.3) |
(2.3) |
% |
|||||||||||
Alphagan®/Combigan® |
91.6 |
98.1 |
(6.5) |
(6.6) |
% |
|||||||||||
Lumigan®/Ganfort® |
62.1 |
73.0 |
(10.9) |
(14.9) |
% |
|||||||||||
Ozurdex® |
29.9 |
27.6 |
2.3 |
8.3 |
% |
|||||||||||
Eye Drops |
57.8 |
53.8 |
4.0 |
7.4 |
% |
|||||||||||
Other Eye Care |
19.7 |
16.3 |
3.4 |
20.9 |
% |
|||||||||||
Total Medical Aesthetics |
735.5 |
743.6 |
(8.1) |
(1.1) |
% |
|||||||||||
Facial Aesthetics |
417.5 |
387.5 |
30.0 |
7.7 |
% |
|||||||||||
Botox®Cosmetics |
252.4 |
236.5 |
15.9 |
6.7 |
% |
|||||||||||
Juvederm®Collection |
156.6 |
139.8 |
16.8 |
12.0 |
% |
|||||||||||
Kybella® |
8.5 |
11.2 |
(2.7) |
(24.1) |
% |
|||||||||||
Plastic Surgery |
67.6 |
75.9 |
(8.3) |
(10.9) |
% |
|||||||||||
Breast Implants |
67.6 |
75.9 |
(8.3) |
(10.9) |
% |
|||||||||||
Regenerative Medicine |
128.9 |
137.6 |
(8.7) |
(6.3) |
% |
|||||||||||
Alloderm® |
101.2 |
107.1 |
(5.9) |
(5.5) |
% |
|||||||||||
Other Regenerative Medicine |
27.7 |
30.5 |
(2.8) |
(9.2) |
% |
|||||||||||
Body Contouring |
78.9 |
108.3 |
(29.4) |
(27.1) |
% |
|||||||||||
Coolsculpting®Systems & Add On |
18.2 |
36.4 |
(18.2) |
(50.0) |
% |
|||||||||||
Coolsculpting®Consumables |
60.7 |
71.9 |
(11.2) |
(15.6) |
% |
|||||||||||
Skin Care(3) |
42.6 |
34.3 |
8.3 |
24.2 |
% |
|||||||||||
Total Medical Dermatology |
9.3 |
39.2 |
(29.9) |
(76.3) |
% |
|||||||||||
Aczone® |
1.8 |
21.1 |
(19.3) |
(91.5) |
% |
|||||||||||
Other Medical Dermatology(4) |
7.5 |
18.1 |
(10.6) |
(58.6) |
% |
|||||||||||
Total Neuroscience & Urology |
451.5 |
441.7 |
9.8 |
2.2 |
% |
|||||||||||
Botox®Therapeutics(5) |
447.0 |
422.0 |
25.0 |
5.9 |
% |
|||||||||||
Rapaflo® |
4.5 |
19.7 |
(15.2) |
(77.2) |
% |
|||||||||||
Other Revenues |
16.8 |
15.2 |
1.6 |
10.5 |
% |
|||||||||||
Net Revenues |
$ |
1,785.1 |
$ |
1,826.7 |
$ |
(41.6) |
(2.3) |
% |
||||||||
Operating expenses: |
||||||||||||||||
Cost of sales(1) |
151.0 |
148.7 |
2.3 |
1.5 |
% |
|||||||||||
Selling and marketing |
368.0 |
343.3 |
24.7 |
7.2 |
% |
|||||||||||
General and administrative |
37.6 |
48.1 |
(10.5) |
(21.8) |
% |
|||||||||||
Segment contribution |
$ |
1,228.5 |
$ |
1,286.6 |
$ |
(58.1) |
(4.5) |
% |
||||||||
Segment margin |
68.8 |
% |
70.4 |
% |
(1.6) |
% |
||||||||||
Segment gross margin(2) |
91.5 |
% |
91.9 |
% |
(0.4) |
% |
||||||||||
(1) Excludes amortization and impairment of acquired intangibles including product rights, as well as indirect cost of sales not attributable to segment results. |
||||||||||||||||
(2) Defined as net revenues less segment related cost of sales as a percentage of net revenues. |
||||||||||||||||
(3) Includes SkinMedica® and Latisse®. |
||||||||||||||||
(4) Includes Tazorac® sales of $6.4 million which were previously disclosed separately in the three months ended June 30, 2018. |
||||||||||||||||
(5) Includes Botox® Hyperhidrosis of $17.3 million which was previously disclosed under Medical Dermatology in the three months ended June 30, 2018. |
||||||||||||||||
Six Months Ended June 30, |
Change |
|||||||||||||||
2019 |
2018 |
Dollars |
% |
|||||||||||||
Total Eye Care |
$ |
1,037.1 |
$ |
1,078.1 |
$ |
(41.0) |
(3.8) |
% |
||||||||
Restasis® |
542.6 |
574.0 |
(31.4) |
(5.5) |
% |
|||||||||||
Alphagan®/Combigan® |
174.6 |
182.3 |
(7.7) |
(4.2) |
% |
|||||||||||
Lumigan®/Ganfort® |
119.8 |
139.8 |
(20.0) |
(14.3) |
% |
|||||||||||
Ozurdex® |
60.2 |
53.1 |
7.1 |
13.4 |
% |
|||||||||||
Eye Drops |
107.2 |
100.0 |
7.2 |
7.2 |
% |
|||||||||||
Other Eye Care |
32.7 |
28.9 |
3.8 |
13.1 |
% |
|||||||||||
Total Medical Aesthetics |
1,383.7 |
1,379.2 |
4.5 |
0.3 |
% |
|||||||||||
Facial Aesthetics |
784.0 |
715.2 |
68.8 |
9.6 |
% |
|||||||||||
Botox®Cosmetics |
481.9 |
433.2 |
48.7 |
11.2 |
% |
|||||||||||
Juvederm®Collection |
286.3 |
262.6 |
23.7 |
9.0 |
% |
|||||||||||
Kybella® |
15.8 |
19.4 |
(3.6) |
(18.6) |
% |
|||||||||||
Plastic Surgery |
128.8 |
136.6 |
(7.8) |
(5.7) |
% |
|||||||||||
Breast Implants |
128.8 |
136.6 |
(7.8) |
(5.7) |
% |
|||||||||||
Regenerative Medicine |
251.8 |
265.8 |
(14.0) |
(5.3) |
% |
|||||||||||
Alloderm® |
196.2 |
206.6 |
(10.4) |
(5.0) |
% |
|||||||||||
Other Regenerative Medicine |
55.6 |
59.2 |
(3.6) |
(6.1) |
% |
|||||||||||
Body Contouring |
141.8 |
195.4 |
(53.6) |
(27.4) |
% |
|||||||||||
Coolsculpting®Systems & Add On |
33.3 |
70.1 |
(36.8) |
(52.5) |
% |
|||||||||||
Coolsculpting®Consumables |
108.5 |
125.3 |
(16.8) |
(13.4) |
% |
|||||||||||
Skin Care(3) |
77.3 |
66.2 |
11.1 |
16.8 |
% |
|||||||||||
Total Medical Dermatology |
15.4 |
75.9 |
(60.5) |
(79.7) |
% |
|||||||||||
Aczone® |
3.4 |
37.1 |
(33.7) |
(90.8) |
% |
|||||||||||
Other Medical Dermatology(4) |
12.0 |
38.8 |
(26.8) |
(69.1) |
% |
|||||||||||
Total Neuroscience & Urology |
860.9 |
840.3 |
20.6 |
2.5 |
% |
|||||||||||
Botox®Therapeutics(5) |
844.6 |
797.8 |
46.8 |
5.9 |
% |
|||||||||||
Rapaflo® |
16.3 |
42.5 |
(26.2) |
(61.6) |
% |
|||||||||||
Other Revenues |
30.9 |
31.8 |
(0.9) |
(2.8) |
% |
|||||||||||
Net Revenues |
$ |
3,328.0 |
$ |
3,405.3 |
$ |
(77.3) |
(2.3) |
% |
||||||||
Operating expenses: |
||||||||||||||||
Cost of sales(1) |
271.1 |
282.9 |
(11.8) |
(4.2) |
% |
|||||||||||
Selling and marketing |
724.8 |
656.5 |
68.3 |
10.4 |
% |
|||||||||||
General and administrative |
92.2 |
98.3 |
(6.1) |
(6.2) |
% |
|||||||||||
Segment contribution |
$ |
2,239.9 |
$ |
2,367.6 |
$ |
(127.7) |
(5.4) |
% |
||||||||
Segment margin |
67.3 |
% |
69.5 |
% |
(2.2) |
% |
||||||||||
Segment gross margin(2) |
91.9 |
% |
91.7 |
% |
0.2 |
% |
||||||||||
(1) Excludes amortization and impairment of acquired intangibles including product rights, as well as indirect cost of sales not attributable to segment results. |
||||||||||||||||
(2) Defined as net revenues less segment related cost of sales as a percentage of net revenues. |
||||||||||||||||
(3) Includes SkinMedica® and Latisse®. |
||||||||||||||||
(4) Includes Tazorac® sales of $15.8 million which were previously disclosed separately in the six months ended June 30, 2018. |
||||||||||||||||
(5) Includes Botox® Hyperhidrosis of $34.6 million which was previously disclosed under Medical Dermatology in the six months ended June 30, 2018. |
||||||||||||||||
The following table details Allergan plc's product revenue for significant promoted products within the US General Medicine segment for the three and six months ended June 30, 2019 and 2018. |
||||||||||||||||
Table 10 |
||||||||||||||||
ALLERGAN PLC |
||||||||||||||||
US General Medicine Product Revenue |
||||||||||||||||
(Unaudited; in millions) |
||||||||||||||||
Three Months Ended June 30, |
Change |
|||||||||||||||
2019 |
2018 |
Dollars |
% |
|||||||||||||
Total Central Nervous System (CNS) |
$ |
365.2 |
$ |
269.9 |
$ |
95.3 |
35.3 |
% |
||||||||
Vraylar® |
196.1 |
114.2 |
81.9 |
71.7 |
% |
|||||||||||
Viibryd®/Fetzima® |
107.8 |
86.7 |
21.1 |
24.3 |
% |
|||||||||||
Saphris® |
32.6 |
33.8 |
(1.2) |
(3.6) |
% |
|||||||||||
Namzaric® |
22.6 |
31.8 |
(9.2) |
(28.9) |
% |
|||||||||||
Namenda ®(3) |
6.1 |
3.4 |
2.7 |
79.4 |
% |
|||||||||||
Total Gastrointestinal (GI) |
419.2 |
431.9 |
(12.7) |
(2.9) |
% |
|||||||||||
Linzess® |
196.0 |
191.8 |
4.2 |
2.2 |
% |
|||||||||||
Zenpep® |
70.0 |
55.5 |
14.5 |
26.1 |
% |
|||||||||||
Carafate®/Sulcrate® |
56.2 |
54.3 |
1.9 |
3.5 |
% |
|||||||||||
Viberzi® |
50.8 |
44.9 |
5.9 |
13.1 |
% |
|||||||||||
Asacol®/Delzicol® |
31.6 |
32.6 |
(1.0) |
(3.1) |
% |
|||||||||||
Canasa®/Salofalk® |
8.0 |
45.0 |
(37.0) |
(82.2) |
% |
|||||||||||
Other GI |
6.6 |
7.8 |
(1.2) |
(15.4) |
% |
|||||||||||
Total Women's Health |
226.0 |
196.5 |
29.5 |
15.0 |
% |
|||||||||||
Lo Loestrin® |
145.5 |
127.8 |
17.7 |
13.8 |
% |
|||||||||||
Liletta® |
21.9 |
15.5 |
6.4 |
41.3 |
% |
|||||||||||
Other Women's Health(4)(5) |
58.6 |
53.2 |
5.4 |
10.2 |
% |
|||||||||||
Total Anti-Infectives |
91.4 |
79.8 |
11.6 |
14.5 |
% |
|||||||||||
Teflaro® |
37.0 |
32.4 |
4.6 |
14.2 |
% |
|||||||||||
Avycaz® |
26.7 |
23.5 |
3.2 |
13.6 |
% |
|||||||||||
Dalvance® |
20.3 |
17.7 |
2.6 |
14.7 |
% |
|||||||||||
Other Anti-Infectives |
7.4 |
6.2 |
1.2 |
19.4 |
% |
|||||||||||
Diversified Brands |
306.0 |
284.9 |
21.1 |
7.4 |
% |
|||||||||||
Bystolic®/Byvalson® |
150.5 |
148.1 |
2.4 |
1.6 |
% |
|||||||||||
Armour Thyroid |
56.7 |
49.2 |
7.5 |
15.2 |
% |
|||||||||||
Savella® |
22.3 |
19.1 |
3.2 |
16.8 |
% |
|||||||||||
Other Diversified Brands(6)(7) |
76.5 |
68.5 |
8.0 |
11.7 |
% |
|||||||||||
Other Revenues |
47.9 |
57.0 |
(9.1) |
(16.0) |
% |
|||||||||||
Net revenues |
$ |
1,455.7 |
$ |
1,320.0 |
$ |
135.7 |
10.3 |
% |
||||||||
Operating expenses: |
||||||||||||||||
Cost of sales(1) |
231.3 |
201.8 |
29.5 |
14.6 |
% |
|||||||||||
Selling and marketing |
250.1 |
254.8 |
(4.7) |
(1.8) |
% |
|||||||||||
General and administrative |
30.4 |
34.7 |
(4.3) |
(12.4) |
% |
|||||||||||
Segment contribution |
$ |
943.9 |
$ |
828.7 |
$ |
115.2 |
13.9 |
% |
||||||||
Segment margin |
64.8 |
% |
62.8 |
% |
2.0 |
% |
||||||||||
Segment gross margin(2) |
84.1 |
% |
84.7 |
% |
(0.6) |
% |
||||||||||
(1) Excludes amortization and impairment of acquired intangibles including product rights, as well as indirect cost of sales not attributable to segment results. |
||||||||||||||||
(2) Defined as net revenues less segment related cost of sales as a percentage of net revenues. |
||||||||||||||||
(3) Includes Namenda XR® and Namenda® IR. |
||||||||||||||||
(4) Includes Estrace® Cream sales of $13.1 million which were previously disclosed separately in the three months ended June 30, 2018. |
||||||||||||||||
(5) Includes Minastrin® 24 sales of $0.8 million which were previously disclosed separately in the three months ended June 30, 2018. |
||||||||||||||||
(6) Includes Lexapro® sales of $14.5 million which were previously disclosed separately in the three months ended June 30, 2018. |
||||||||||||||||
(7) Includes PacPharma sales of $3.7 million which were previously disclosed separately in the three months ended June 30, 2018. |
||||||||||||||||
Six Months Ended June 30, |
Change |
|||||||||||||||
2019 |
2018 |
Dollars |
% |
|||||||||||||
Total Central Nervous System (CNS) |
$ |
658.7 |
$ |
532.7 |
$ |
126.0 |
23.7 |
% |
||||||||
Namenda® |
15.6 |
44.0 |
(28.4) |
(64.5) |
% |
|||||||||||
Namzaric® |
46.0 |
65.2 |
(19.2) |
(29.4) |
% |
|||||||||||
Viibryd®/Fetzima® |
192.8 |
158.4 |
34.4 |
21.7 |
% |
|||||||||||
Saphris® |
64.5 |
66.5 |
(2.0) |
(3.0) |
% |
|||||||||||
Vraylar™ |
339.8 |
198.6 |
141.2 |
71.1 |
% |
|||||||||||
Total Gastrointestinal (GI) |
777.4 |
820.6 |
(43.2) |
(5.3) |
% |
|||||||||||
Linzess® |
357.3 |
351.1 |
6.2 |
1.8 |
% |
|||||||||||
Asacol®/Delzicol® |
56.3 |
70.8 |
(14.5) |
(20.5) |
% |
|||||||||||
Carafate®/Sulcrate® |
110.5 |
110.3 |
0.2 |
0.2 |
% |
|||||||||||
Zenpep® |
133.0 |
108.4 |
24.6 |
22.7 |
% |
|||||||||||
Canasa®/Salofalk® |
18.2 |
83.6 |
(65.4) |
(78.2) |
% |
|||||||||||
Viberzi® |
88.0 |
80.8 |
7.2 |
8.9 |
% |
|||||||||||
Other GI |
14.1 |
15.6 |
(1.5) |
(9.6) |
% |
|||||||||||
Total Women's Health |
427.0 |
359.8 |
67.2 |
18.7 |
% |
|||||||||||
Lo Loestrin® |
271.3 |
242.4 |
28.9 |
11.9 |
% |
|||||||||||
Liletta® |
36.7 |
23.6 |
13.1 |
55.5 |
% |
|||||||||||
Other Women's Health(4)(5) |
119.0 |
93.8 |
25.2 |
26.9 |
% |
|||||||||||
Total Anti-Infectives |
173.0 |
151.4 |
21.6 |
14.3 |
% |
|||||||||||
Teflaro® |
70.5 |
64.6 |
5.9 |
9.1 |
% |
|||||||||||
Dalvance® |
32.3 |
29.6 |
2.7 |
9.1 |
% |
|||||||||||
Avycaz® |
56.4 |
45.3 |
11.1 |
24.5 |
% |
|||||||||||
Other Anti-Infectives |
13.8 |
11.9 |
1.9 |
16.0 |
% |
|||||||||||
Diversified Brands |
576.9 |
559.8 |
17.1 |
3.1 |
% |
|||||||||||
Bystolic®/Byvalson® |
278.8 |
280.9 |
(2.1) |
(0.7) |
% |
|||||||||||
Armour Thyroid |
106.7 |
97.4 |
9.3 |
9.5 |
% |
|||||||||||
Savella® |
43.0 |
39.0 |
4.0 |
10.3 |
% |
|||||||||||
Other Diversified Brands(6)(7) |
148.4 |
142.5 |
5.9 |
4.1 |
% |
|||||||||||
Other Revenues |
92.6 |
119.4 |
(26.8) |
(22.4) |
% |
|||||||||||
Net revenues |
$ |
2,705.6 |
$ |
2,543.7 |
$ |
161.9 |
6.4 |
% |
||||||||
Operating expenses: |
||||||||||||||||
Cost of sales(1) |
421.8 |
384.4 |
37.4 |
9.7 |
% |
|||||||||||
Selling and marketing |
460.6 |
480.3 |
(19.7) |
(4.1) |
% |
|||||||||||
General and administrative |
74.2 |
73.6 |
0.6 |
0.8 |
% |
|||||||||||
Segment contribution |
$ |
1,749.0 |
$ |
1,605.4 |
$ |
143.6 |
8.9 |
% |
||||||||
Segment margin |
64.6 |
% |
63.1 |
% |
1.5 |
% |
||||||||||
Segment gross margin(2) |
84.4 |
% |
84.9 |
% |
(0.5) |
% |
||||||||||
(1) Excludes amortization and impairment of acquired intangibles including product rights, as well as indirect cost of sales not attributable to segment results. |
||||||||||||||||
(2) Defined as net revenues less segment related cost of sales as a percentage of net revenues. |
||||||||||||||||
(3) Includes Namenda XR® and Namenda® IR. |
||||||||||||||||
(4) Includes Estrace® Cream sales of $19.5 million which were previously disclosed separately in the six months ended June 30, 2018. |
||||||||||||||||
(5) Includes Minastrin® 24 sales of $6.0 million which were previously disclosed separately in the six months ended June 30, 2018. |
||||||||||||||||
(6) Includes Lexapro® sales of $29.2 million which were previously disclosed separately in the six months ended June 30, 2018. |
||||||||||||||||
(7) Includes PacPharma sales of $8.1 million which were previously disclosed separately in the six months ended June 30, 2018. |
||||||||||||||||
The following table details Allergan plc's product revenue for significant promoted products within the International segment for the three and six months ended June 30, 2019 and 2018. |
||||||||||||||||
Table 11 |
||||||||||||||||
ALLERGAN PLC |
||||||||||||||||
International Product Revenue |
||||||||||||||||
(Unaudited; in millions) |
||||||||||||||||
Three Months Ended June 30, |
Change |
|||||||||||||||
2019 |
2018 |
Dollars |
% |
|||||||||||||
Total Eye Care |
$ |
327.0 |
$ |
353.7 |
$ |
(26.7) |
(7.5) |
% |
||||||||
Lumigan®/Ganfort® |
90.4 |
100.5 |
(10.1) |
(10.0) |
% |
|||||||||||
Alphagan®/Combigan® |
40.9 |
44.6 |
(3.7) |
(8.3) |
% |
|||||||||||
Ozurdex® |
81.0 |
67.9 |
13.1 |
19.3 |
% |
|||||||||||
Eye Drops(3) |
57.3 |
72.4 |
(15.1) |
(20.9) |
% |
|||||||||||
Restasis® |
11.9 |
16.0 |
(4.1) |
(25.6) |
% |
|||||||||||
Other Eye Care |
45.5 |
52.3 |
(6.8) |
(13.0) |
% |
|||||||||||
Total Medical Aesthetics |
357.2 |
409.8 |
(52.6) |
(12.8) |
% |
|||||||||||
Facial Aesthetics |
349.1 |
329.8 |
19.3 |
5.9 |
% |
|||||||||||
Botox®Cosmetics |
175.8 |
171.4 |
4.4 |
2.6 |
% |
|||||||||||
Juvederm®Collection |
172.7 |
156.1 |
16.6 |
10.6 |
% |
|||||||||||
Belkyra®(Kybella®) |
0.6 |
2.3 |
(1.7) |
(73.9) |
% |
|||||||||||
Plastic Surgery |
(31.1) |
40.3 |
(71.4) |
(177.2) |
% |
|||||||||||
Breast Implants |
(31.4) |
39.9 |
(71.3) |
(178.7) |
% |
|||||||||||
Other Plastic Surgery |
0.3 |
0.4 |
(0.1) |
(25.0) |
% |
|||||||||||
Regenerative Medicine |
3.6 |
4.7 |
(1.1) |
(23.4) |
% |
|||||||||||
Alloderm® |
2.2 |
2.3 |
(0.1) |
(4.3) |
% |
|||||||||||
Other Regenerative Medicine |
1.4 |
2.4 |
(1.0) |
(41.7) |
% |
|||||||||||
Body Contouring |
31.9 |
30.9 |
1.0 |
3.2 |
% |
|||||||||||
Coolsculpting®Systems & Add On Applicators |
11.6 |
12.4 |
(0.8) |
(6.5) |
% |
|||||||||||
Coolsculpting®Consumables |
20.3 |
18.5 |
1.8 |
9.7 |
% |
|||||||||||
Skin Care |
3.7 |
4.1 |
(0.4) |
(9.8) |
% |
|||||||||||
Botox® Therapeutics and Other |
148.9 |
166.6 |
(17.7) |
(10.6) |
% |
|||||||||||
Botox®Therapeutics |
98.8 |
104.6 |
(5.8) |
(5.5) |
% |
|||||||||||
Asacol®/Delzicol® |
9.7 |
12.4 |
(2.7) |
(21.8) |
% |
|||||||||||
Constella® |
4.8 |
6.4 |
(1.6) |
(25.0) |
% |
|||||||||||
Other Products |
35.6 |
43.2 |
(7.6) |
(17.6) |
% |
|||||||||||
Other Revenues |
14.6 |
18.8 |
(4.2) |
(22.3) |
% |
|||||||||||
Net revenues |
$ |
847.7 |
$ |
948.9 |
$ |
(101.2) |
(10.7) |
% |
||||||||
Operating expenses: |
||||||||||||||||
Cost of sales(1) |
145.6 |
139.4 |
6.2 |
4.4 |
% |
|||||||||||
Selling and marketing |
253.6 |
246.2 |
7.4 |
3.0 |
% |
|||||||||||
General and administrative |
28.4 |
33.9 |
(5.5) |
(16.2) |
% |
|||||||||||
Segment contribution |
$ |
420.1 |
$ |
529.4 |
$ |
(109.3) |
(20.6) |
% |
||||||||
Segment margin |
49.6 |
% |
55.8 |
% |
(6.2) |
% |
||||||||||
Segment gross margin(2) |
82.8 |
% |
85.3 |
% |
(2.5) |
% |
||||||||||
(1) Excludes amortization and impairment of acquired intangibles including product rights, as well as indirect cost of sales not attributable to segment results. |
||||||||||||||||
(2) Defined as net revenues less segment related cost of sales as a percentage of net revenues. |
||||||||||||||||
(3) Includes Optive® sales of $30.7 million which were previously disclosed separately in the three months ended June 30, 2018. |
||||||||||||||||
Six Months Ended June 30, |
Change |
|||||||||||||||
2019 |
2018 |
Dollars |
% |
|||||||||||||
Total Eye Care |
$ |
618.8 |
$ |
697.4 |
$ |
(78.6) |
(11.3) |
% |
||||||||
Lumigan®/Ganfort® |
175.5 |
200.9 |
(25.4) |
(12.6) |
% |
|||||||||||
Alphagan®/Combigan® |
78.5 |
88.8 |
(10.3) |
(11.6) |
% |
|||||||||||
Ozurdex® |
144.1 |
132.3 |
11.8 |
8.9 |
% |
|||||||||||
Eye Drops(3) |
112.7 |
141.2 |
(28.5) |
(20.2) |
% |
|||||||||||
Restasis® |
22.3 |
34.3 |
(12.0) |
(35.0) |
% |
|||||||||||
Other Eye Care |
85.7 |
99.9 |
(14.2) |
(14.2) |
% |
|||||||||||
Total Medical Aesthetics |
710.0 |
768.3 |
(58.3) |
(7.6) |
% |
|||||||||||
Facial Aesthetics |
655.9 |
625.9 |
30.0 |
4.8 |
% |
|||||||||||
Botox®Cosmetics |
323.2 |
320.0 |
3.2 |
1.0 |
% |
|||||||||||
Juvederm®Collection |
330.5 |
302.2 |
28.3 |
9.4 |
% |
|||||||||||
Belkyra®(Kybella®) |
2.2 |
3.7 |
(1.5) |
(40.5) |
% |
|||||||||||
Plastic Surgery |
(19.5) |
84.8 |
(104.3) |
(123.0) |
% |
|||||||||||
Breast Implants |
(20.2) |
84.0 |
(104.2) |
(124.0) |
% |
|||||||||||
Other Plastic Surgery |
0.7 |
0.8 |
(0.1) |
(12.5) |
% |
|||||||||||
Regenerative Medicine |
6.9 |
9.6 |
(2.7) |
(28.1) |
% |
|||||||||||
Alloderm® |
3.8 |
4.5 |
(0.7) |
(15.6) |
% |
|||||||||||
Other Regenerative Medicine |
3.1 |
5.1 |
(2.0) |
(39.2) |
% |
|||||||||||
Body Contouring |
60.3 |
40.1 |
20.2 |
50.4 |
% |
|||||||||||
Coolsculpting®Systems & Add On Applicators |
22.2 |
13.5 |
8.7 |
64.4 |
% |
|||||||||||
Coolsculpting®Consumables |
38.1 |
26.6 |
11.5 |
43.2 |
% |
|||||||||||
Skin Care |
6.4 |
7.9 |
(1.5) |
(19.0) |
% |
|||||||||||
Botox® Therapeutics and Other |
287.7 |
316.3 |
(28.6) |
(9.0) |
% |
|||||||||||
Botox®Therapeutics |
192.7 |
200.8 |
(8.1) |
(4.0) |
% |
|||||||||||
Asacol®/Delzicol® |
20.0 |
24.1 |
(4.1) |
(17.0) |
% |
|||||||||||
Constella® |
10.3 |
12.0 |
(1.7) |
(14.2) |
% |
|||||||||||
Other Products |
64.7 |
79.4 |
(14.7) |
(18.5) |
% |
|||||||||||
Other Revenues |
32.7 |
30.9 |
1.8 |
5.8 |
% |
|||||||||||
Net revenues |
$ |
1,649.2 |
$ |
1,812.9 |
$ |
(163.7) |
(9.0) |
% |
||||||||
Operating expenses: |
||||||||||||||||
Cost of sales(1) |
255.3 |
260.3 |
(5.0) |
(1.9) |
% |
|||||||||||
Selling and marketing |
491.2 |
491.9 |
(0.7) |
(0.1) |
% |
|||||||||||
General and administrative |
54.1 |
65.3 |
(11.2) |
(17.2) |
% |
|||||||||||
Segment contribution |
$ |
848.6 |
$ |
995.4 |
$ |
(146.8) |
(14.7) |
% |
||||||||
Segment margin |
51.5 |
% |
54.9 |
% |
(3.4) |
% |
||||||||||
Segment gross margin(2) |
84.5 |
% |
85.6 |
% |
(1.1) |
% |
||||||||||
(1) Excludes amortization and impairment of acquired intangibles including product rights, as well as indirect cost of sales not attributable to segment results. |
||||||||||||||||
(2) Defined as net revenues less segment related cost of sales as a percentage of net revenues. |
||||||||||||||||
(3) Includes Optive® sales of $58.5 million which were previously disclosed separately in the six months ended June 30, 2018. |
||||||||||||||||
The following table provides a reconciliation of anticipated GAAP loss / income from continuing operations to non-GAAP performance net income attributable to shareholders for the twelve months ending December 31, 2019: |
|||
Table 12 |
|||
Twelve months ending |
|||
(in millions, except per share information) |
LOW |
||
GAAP income/(loss) from continuing operations attributable to shareholders |
$ |
(3,957.0) |
|
Adjusted for: |
|||
Amortization |
5,690.0 |
||
Acquisition, divestiture, licensing and other non-recurring charges |
113.0 |
||
Accretion and fair-value adjustments to contingent consideration |
58.0 |
||
Impairment/asset sales and related costs |
4,115.0 |
||
Non-acquisition restructurings, including Global Supply Chain initiatives |
6.0 |
||
Legal settlements |
18.0 |
||
Income taxes on items above and other discrete income tax |
(548.0) |
||
Non-GAAP performance net income attributable to shareholders |
5,495.0 |
||
Diluted earnings per share |
|||
Diluted (loss) / income per share from continuing operations attributable to |
$ |
(12.03) |
|
Non-GAAP performance diluted net income per share attributable to |
$ |
16.55 |
|
Basic weighted average ordinary shares outstanding |
329.0 |
||
Effect of dilutive securities: |
|||
Dilutive shares |
3.0 |
||
Diluted weighted average ordinary shares outstanding |
332.0 |
YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE
Notice
The "Yes" link below will take you out of the AbbVie family of websites.
Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.
The Internet site that you have requested may not be optimized to your screen size.
Do you wish to leave this site?